Neuronetics Technology Advancements Enhance Depression Treatment
Medical technology company, Neuronetics, Inc. (NASDAQ: STIM), announced significant updates to its NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting system for NeuroStar providers. The standout feature of this update is its ability to proactively notify NeuroStar providers when patients exhibit signs of relapse or experience changes in their mental health post-NeuroStar transcranial magnetic stimulation (TMS) treatment.
Cory Anderson, SVP of R&D and Clinical at Neuronetics, said, “The NeuroStar and TrakStar software updates are set to usher in a new era of patient care and data management. We are committed to ensuring that our NeuroStar technology and TrakStar platform can aid practices in delivering the best possible outcomes for patients struggling to find relief from the debilitating symptoms of depression.”
Highlights
NeuroStar’s innovative software update is set to redefine the user experience for all legacy NeuroStar systems while maintaining the original workflow. The enhancement includes a new user interface and software platform, ensuring a uniform, seamless experience across all devices.
The software provides real-time notifications that empower practices to swiftly identify patients who may require a follow-up NeuroStar treatment or clinical evaluation.
TrakStar’s software has also been upgraded to significantly enhance patient care and practice management.
The NeuroStar software will be rolled out in phases during the 4th quarter, starting today. Simultaneously, the TrakStar software is now available to all customers.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
